Caris Life Sciences, Moderna Ink Strategic Partnership Agreement

Published on: 

Collaboration to focus on advancing mRNA-based oncology therapeutics.

Caris Life Sciences, an artificial intelligence (AI) TechBio company, announced a new agreement with Moderna in support of the latter’s oncology and novel therapeutics initiatives. Per the agreement, Moderna will utilize Caris' vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for its oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.


"We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives," said David Spetzler, MS, PhD, MBA, President, Caris Life Sciences. "The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna's innovative medicines."

Reference: Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics. PR Newswire. October 24, 2023. Accessed October 25, 2023.